ReviewTropical diseases, travel medicine and vaccines2025
A comprehensive phenotypic and genotypic taxonomic review of Leishmania (Leishmania) poncei n. sp. (Kinetoplastea: Trypanosomatidae): a novel agent of cutaneous (non-ulcerated) and visceral leishmaniasis in Honduras, Central America.
Review in Tropical diseases, travel medicine and vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Detection ofTropical medicine and infectious disease · 2026Article
- Revisiting Leishmania (Viannia) lainsoni Silveira, Shaw, Braga, and Ishikawa, 1987: current knowledge and emerging perspectives.Parasites & vectors · 2026Review
- A decade of health research capacity building in Honduras: institutional transformation, challenges, and lessons learned.Global health action · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Non-ulcerated cutaneous leishmaniasis (NUCL) is an atypical clinical form of leishmaniasis first described, in 1988, by Ponce and collaborators, in Honduras, Central America, characterized by isolated or disseminated closed skin lesions appearing as papules, nodules, or infiltrated plaques, primarily in adolescents and young adults. Leishmania (L.) chagasi was then identified as the causal agent of both NUCL and American visceral leishmaniasis (AVL) in Honduras, though NUCL has been reported as more prevalent. However, due to the uncertain taxonomic classification of the NUCL-causing parasite, especially since L. (L.) chagasi has not been associated to this form of the disease in South America, this study conducted a comprehensive taxonomic review incorporating phenotypic (biological and clinical-immunopathological) and genotypic (genomic/molecular) analyses. Biologically, Honduran parasite-LPG does not have Gal (β1,4) Man (α1)-PO4 side chains common to all Leishmania LPGs. From a clinical-pathogenic perspective, NUCL is unique, it does not ulcerate like cutaneous leishmaniasis due to L. (L.) chagasi or L. (L.) infantum. Molecular findings showed that the Honduran parasite is more ancestral than all known viscerotropic Leishmania species, exhibited an unprecedented structural variation on chromosome 17 with the highest frequency of genomic SNPs, formed a distinct phylogenetic lineage, and displayed a homozygous SNP profile typical of a parental (non-hybrid) parasite. Building on these findings, a new species, Leishmania (Leishmania) poncei n. sp. (Kinetoplastea: Trypanosomatidae), is proposed in honor of Professor Carlos Ponce, who first described NUCL in Honduras. This study formally classifies L. (L.) poncei n. sp. as a novel Leishmania species responsible for both NUCL and AVL in Honduras, Central America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.